{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:55:31Z","timestamp":1791107731365,"version":"4.1.0"},"reference-count":58,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>MYC deregulation is common in human cancer. IG-MYC translocations that are modeled in E\u03bc-Myc mice occur in almost all cases of Burkitt lymphoma as well as in other B-cell lymphoproliferative disorders. Deregulated expression of MYC results in increased mTOR complex 1 (mTORC1) signaling. As tumors with mTORC1 activation are sensitive to mTORC1 inhibition, we used everolimus, a potent and specific mTORC1 inhibitor, to test the requirement for mTORC1 in the initiation and maintenance of E\u03bc-Myc lymphoma. Everolimus selectively cleared premalignant B cells from the bone marrow and spleen, restored a normal pattern of B-cell differentiation, and strongly protected against lymphoma development. Established E\u03bc-Myc lymphoma also regressed after everolimus therapy. Therapeutic response correlated with a cellular senescence phenotype and induction of p53 activity. Therefore, mTORC1-dependent evasion of senescence is critical for cellular transformation and tumor maintenance by MYC in B lymphocytes.<\/jats:p>\n                  <jats:p>Significance: This work provides novel insights into the requirements for MYC-induced oncogenesis by showing that mTORC1 activity is necessary to bypass senescence during transformation of B lymphocytes. Furthermore, tumor eradication through senescence elicited by targeted inhibition of mTORC1 identifies a previously uncharacterized mechanism responsible for significant anticancer activity of rapamycin analogues and serves as proof-of-concept that senescence can be harnessed for therapeutic benefit. Cancer Discov; 3(1); 82\u201395. \u00a92012 AACR.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 1<\/jats:p>","DOI":"10.1158\/2159-8290.cd-12-0404","type":"journal-article","created":{"date-parts":[[2012,12,15]],"date-time":"2012-12-15T20:44:36Z","timestamp":1355604276000},"page":"82-95","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["The mTORC1 Inhibitor Everolimus Prevents and Treats E\u03bc-\n                    <i>Myc<\/i>\n                    Lymphoma by Restoring Oncogene-Induced Senescence"],"prefix":"10.1158","volume":"3","author":[{"given":"Meaghan","family":"Wall","sequence":"first","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Poortinga","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kym L.","family":"Stanley","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph K.","family":"Lindemann","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bots","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Chan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan J.","family":"Bywater","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Kinross","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan V.","family":"Astle","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Waldeck","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Hannan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Smyth","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross D.","family":"Hannan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky W.","family":"Johnstone","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A.","family":"McArthur","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"},{"name":"Authors' Affiliations: 1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2013,1,13]]},"reference":[{"key":"2022060622573747600_bib1","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1038\/sj.onc.1202746","article-title":"MYC oncogenes and human neoplastic disease","volume":"18","author":"Nesbit","year":"1999","journal-title":"Oncogene"},{"key":"2022060622573747600_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.semcancer.2006.07.015","article-title":"The Myc oncoprotein as a therapeutic target for human cancer","volume":"16","author":"Vita","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"2022060622573747600_bib3","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-09-0889","article-title":"MYC-induced cancer cell energy metabolism and therapeutic opportunities","volume":"15","author":"Dang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022060622573747600_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc2819","article-title":"MYC as a regulator of ribosome biogenesis and protein synthesis","volume":"10","author":"van Riggelen","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2022060622573747600_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.molcel.2010.09.026","article-title":"Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress","volume":"40","author":"Sengupta","year":"2010","journal-title":"Mol Cell"},{"key":"2022060622573747600_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/318533a0","article-title":"The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice","volume":"318","author":"Adams","year":"1985","journal-title":"Nature"},{"key":"2022060622573747600_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0092-8674(86)90361-2","article-title":"The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice","volume":"47","author":"Langdon","year":"1986","journal-title":"Cell"},{"key":"2022060622573747600_bib8","first-page":"1665","article-title":"Multiple mechanisms of tumorigenesis in E mu-myc transgenic mice","volume":"53","author":"Sidman","year":"1993","journal-title":"Cancer Res"},{"key":"2022060622573747600_bib9","doi-asserted-by":"crossref","first-page":"13180","DOI":"10.1073\/pnas.96.23.13180","article-title":"c-Myc enhances protein synthesis and cell size during B lymphocyte development","volume":"96","author":"Iritani","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622573747600_bib10","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood.V84.8.2784.2784","article-title":"Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice","volume":"84","author":"Jacobsen","year":"1994","journal-title":"Blood"},{"key":"2022060622573747600_bib11","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1073\/pnas.0401471101","article-title":"Bim is a suppressor of Myc-induced mouse B cell leukemia","volume":"101","author":"Egle","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622573747600_bib12","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1101\/gad.13.20.2658","article-title":"Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis","volume":"13","author":"Eischen","year":"1999","journal-title":"Genes Dev"},{"key":"2022060622573747600_bib13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nature03845","article-title":"Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants","volume":"436","author":"Hemann","year":"2005","journal-title":"Nature"},{"key":"2022060622573747600_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/348331a0","article-title":"Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2","volume":"348","author":"Strasser","year":"1990","journal-title":"Nature"},{"key":"2022060622573747600_bib15","doi-asserted-by":"crossref","first-page":"11209","DOI":"10.1158\/0008-5472.CAN-06-4351","article-title":"c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation","volume":"67","author":"Ravitz","year":"2007","journal-title":"Cancer Res"},{"key":"2022060622573747600_bib16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature07449","article-title":"Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency","volume":"456","author":"Barna","year":"2008","journal-title":"Nature"},{"key":"2022060622573747600_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ccr.2012.05.019","article-title":"Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53","volume":"22","author":"Bywater","year":"2012","journal-title":"Cancer Cell"},{"key":"2022060622573747600_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1084\/jem.167.2.353","article-title":"The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells","volume":"167","author":"Harris","year":"1988","journal-title":"J Exp Med"},{"key":"2022060622573747600_bib19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature02369","article-title":"Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy","volume":"428","author":"Wendel","year":"2004","journal-title":"Nature"},{"key":"2022060622573747600_bib20","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1074\/jbc.M309999200","article-title":"AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression","volume":"279","author":"Gera","year":"2004","journal-title":"J Biol Chem"},{"key":"2022060622573747600_bib21","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2007-09-111856","article-title":"Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation","volume":"112","author":"Wall","year":"2008","journal-title":"Blood"},{"key":"2022060622573747600_bib22","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1158\/0008-5472.CAN-06-0419","article-title":"Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo","volume":"66","author":"Wendel","year":"2006","journal-title":"Cancer Res"},{"key":"2022060622573747600_bib23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas","volume":"445","author":"Xue","year":"2007","journal-title":"Nature"},{"key":"2022060622573747600_bib24","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/emboj.2011.69","article-title":"p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype","volume":"30","author":"Freund","year":"2011","journal-title":"EMBO J"},{"key":"2022060622573747600_bib25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0092-8674(03)00401-X","article-title":"Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence","volume":"113","author":"Narita","year":"2003","journal-title":"Cell"},{"key":"2022060622573747600_bib26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ccr.2009.12.043","article-title":"Tumor stroma-derived TGF-beta limits Myc-driven lymphomagenesis via Suv39h1-dependent senescence","volume":"17","author":"Reimann","year":"2010","journal-title":"Cancer Cell"},{"key":"2022060622573747600_bib27","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/emboj\/16.6.1391","article-title":"Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo","volume":"16","author":"Komarova","year":"1997","journal-title":"EMBO J"},{"key":"2022060622573747600_bib28","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/0092-8674(93)90719-7","article-title":"p53-dependent apoptosis modulates the cytotoxicity of anticancer agents","volume":"74","author":"Lowe","year":"1993","journal-title":"Cell"},{"key":"2022060622573747600_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: a further update","volume":"408","author":"Bain","year":"2007","journal-title":"Biochem J"},{"key":"2022060622573747600_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"2022060622573747600_bib31","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"2022060622573747600_bib32","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1182\/blood-2008-02-137752","article-title":"Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia","volume":"113","author":"Crazzolara","year":"2009","journal-title":"Blood"},{"key":"2022060622573747600_bib33","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0804821105","article-title":"mTORC1 promotes survival through translational control of Mcl-1","volume":"105","author":"Mills","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622573747600_bib34","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1101\/gad.1971610","article-title":"The essence of senescence","volume":"24","author":"Kuilman","year":"2010","journal-title":"Genes Dev"},{"key":"2022060622573747600_bib35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ncb2004","article-title":"Cdk2 suppresses cellular senescence induced by the c-myc oncogene","volume":"12","author":"Campaner","year":"2010","journal-title":"Nat Cell Biol"},{"key":"2022060622573747600_bib36","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1101\/gad.585710","article-title":"The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance","volume":"24","author":"van Riggelen","year":"2010","journal-title":"Genes Dev"},{"key":"2022060622573747600_bib37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2010.10.002","article-title":"CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation","volume":"18","author":"Rakhra","year":"2010","journal-title":"Cancer Cell"},{"key":"2022060622573747600_bib38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccr.2006.10.003","article-title":"A negative feedback signaling network underlies oncogene-induced senescence","volume":"10","author":"Courtois-Cox","year":"2006","journal-title":"Cancer Cell"},{"key":"2022060622573747600_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.molcel.2011.02.020","article-title":"Activation of the PIK3CA\/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis","volume":"42","author":"Kennedy","year":"2011","journal-title":"Mol Cell"},{"key":"2022060622573747600_bib40","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1101\/gad.187252.112","article-title":"Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis","volume":"26","author":"Vredeveld","year":"2012","journal-title":"Genes Dev"},{"key":"2022060622573747600_bib41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"Majumder","year":"2004","journal-title":"Nat Med"},{"key":"2022060622573747600_bib42","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/1940-6207.CAPR-09-0169","article-title":"Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer","volume":"2","author":"Seager","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"2022060622573747600_bib43","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1158\/0008-5472.CAN-08-4645","article-title":"Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model","volume":"69","author":"Raimondi","year":"2009","journal-title":"Cancer Res"},{"key":"2022060622573747600_bib44","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-05-2170","article-title":"Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ","volume":"12","author":"Namba","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022060622573747600_bib45","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.2353\/ajpath.2010.091050","article-title":"Rapamycin extends maximal lifespan in cancer-prone mice","volume":"176","author":"Anisimov","year":"2010","journal-title":"Am J Pathol"},{"key":"2022060622573747600_bib46","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1158\/0008-5472.CAN-06-4490","article-title":"RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer","volume":"67","author":"Mabuchi","year":"2007","journal-title":"Cancer Res"},{"key":"2022060622573747600_bib47","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-05-2447","article-title":"Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis","volume":"66","author":"Yan","year":"2006","journal-title":"Cancer Res"},{"key":"2022060622573747600_bib48","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells","volume":"10","author":"Mondesire","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022060622573747600_bib49","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1073\/pnas.0502256102","article-title":"A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance","volume":"102","author":"Xing","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622573747600_bib50","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1158\/1078-0432.CCR-06-2770","article-title":"RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model","volume":"13","author":"Mabuchi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022060622573747600_bib51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","article-title":"The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation","volume":"120","author":"Beuvink","year":"2005","journal-title":"Cell"},{"key":"2022060622573747600_bib52","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"2022060622573747600_bib53","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1073\/pnas.0702294104","article-title":"Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma","volume":"104","author":"Lindemann","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622573747600_bib54","first-page":"699","article-title":"Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma","volume":"36","author":"Stefancikova","year":"2010","journal-title":"Int J Oncol"},{"key":"2022060622573747600_bib55","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1002\/cncr.24430","article-title":"Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas","volume":"115","author":"Robledo","year":"2009","journal-title":"Cancer"},{"key":"2022060622573747600_bib56","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/0008-5472.CAN-10-3289","article-title":"Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737","volume":"71","author":"Wiegmans","year":"2011","journal-title":"Cancer Res"},{"key":"2022060622573747600_bib57","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.173.5.1213","article-title":"Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow","volume":"173","author":"Hardy","year":"1991","journal-title":"J Exp Med"},{"key":"2022060622573747600_bib58","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/3\/1\/82\/1808845\/82.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/3\/1\/82\/1808845\/82.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T18:58:07Z","timestamp":1654541887000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/3\/1\/82\/3420\/The-mTORC1-Inhibitor-Everolimus-Prevents-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,1]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,13]]},"published-print":{"date-parts":[[2013,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-12-0404","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22528523.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528514","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528523","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528520","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528532","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528532.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528520.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528529.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6545726.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528517","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528529","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6545726","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528514.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22528517.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,1]]}}}